249 related articles for article (PubMed ID: 33942396)
1. Pembrolizumab-caused polyradiculoneuropathy as an immune-related adverse event.
Kurashige T; Mito M; Yamamoto H; Sugiura T; Onoe T; Kuraoka K; Nakano K; Torii T
Neuropathology; 2021 Aug; 41(4):266-272. PubMed ID: 33942396
[TBL] [Abstract][Full Text] [Related]
2. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
3. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
4. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
5. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
[TBL] [Abstract][Full Text] [Related]
6. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
7. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab.
Eun Y; Kim IY; Sun JM; Lee J; Cha HS; Koh EM; Kim H; Lee J
Sci Rep; 2019 Oct; 9(1):14039. PubMed ID: 31575933
[TBL] [Abstract][Full Text] [Related]
10. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.
Zimmer L; Goldinger SM; Hofmann L; Loquai C; Ugurel S; Thomas I; Schmidgen MI; Gutzmer R; Utikal JS; Göppner D; Hassel JC; Meier F; Tietze JK; Forschner A; Weishaupt C; Leverkus M; Wahl R; Dietrich U; Garbe C; Kirchberger MC; Eigentler T; Berking C; Gesierich A; Krackhardt AM; Schadendorf D; Schuler G; Dummer R; Heinzerling LM
Eur J Cancer; 2016 Jun; 60():210-25. PubMed ID: 27084345
[TBL] [Abstract][Full Text] [Related]
11. Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline.
Iwama S; Kobayashi T; Yasuda Y; Okuji T; Ito M; Ando M; Zhou X; Yamagami A; Onoue T; Kawaguchi Y; Miyata T; Sugiyama M; Takagi H; Hagiwara D; Suga H; Banno R; Hase T; Morise M; Wakahara K; Yokota K; Kato M; Nishio N; Tanaka C; Miyata K; Ogura A; Ito T; Sawada T; Shimokata T; Niimi K; Ohka F; Ishigami M; Gotoh M; Hashimoto N; Saito R; Kiyoi H; Kajiyama H; Ando Y; Hibi H; Sone M; Akiyama M; Kodera Y; Arima H
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1620-e1630. PubMed ID: 34791304
[TBL] [Abstract][Full Text] [Related]
12. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment.
Kim KH; Hur JY; Cho J; Ku BM; Koh J; Koh JY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ; Shin EC
Oncoimmunology; 2020; 9(1):1722023. PubMed ID: 32076579
[TBL] [Abstract][Full Text] [Related]
13. [Managing the Adverse Effects Related to Immune Checkpoint Inhibitors].
Kuo HH; Chen WW
Hu Li Za Zhi; 2018 Jun; 65(3):88-95. PubMed ID: 29790143
[TBL] [Abstract][Full Text] [Related]
14. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
15. Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction.
Kunimasa K; Isei T; Nakamura H; Kimura M; Inoue T; Tamiya M; Nishino K; Kumagai T; Nakatsuka SI; Endo H; Inoue M; Imamura F
Invest New Drugs; 2018 Dec; 36(6):1138-1142. PubMed ID: 29947012
[TBL] [Abstract][Full Text] [Related]
16. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.
Zhang ML; Neyaz A; Patil D; Chen J; Dougan M; Deshpande V
Histopathology; 2020 Jan; 76(2):233-243. PubMed ID: 31361907
[TBL] [Abstract][Full Text] [Related]
17. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment.
Psimaras D; Velasco R; Birzu C; Tamburin S; Lustberg M; Bruna J; Argyriou AA
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S74-S85. PubMed ID: 31393660
[TBL] [Abstract][Full Text] [Related]
19. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Beck TN; Kudinov AE; Dulaimi E; Boumber Y
BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
[TBL] [Abstract][Full Text] [Related]
20. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
